Drug Profile
Pregabalin controlled release - Alvogen Korea
Alternative Names: KW-21052Latest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator KunWha Pharmaceutical
- Developer Alvogen Korea
- Class Aminobutyric acids; Analgesics; Antiepileptic drugs; Anxiolytics; Gabapentinoids; Neuroprotectants; Small molecules
- Mechanism of Action CACNA2D1 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neuropathic pain
Most Recent Events
- 23 Nov 2020 Alvogen Korea plans a phase III trial for Neuropathic pain in India (CTRI2020-08-027186)
- 28 Apr 2019 No recent reports of development identified for phase-I development in Neuropathic-pain in South Korea (PO, Controlled release)
- 07 Mar 2016 Phase-I clinical trials in Neuropathic pain in South Korea (PO)